


NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
LEO Pharma (Toripalimab)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency for Equality Cancer Black Care	Board of Community Health Councils in Wales
Cancer Laryngectomee Trust	British National Formulary
Cancer52	
0 () 1	
	Department of Health - Northern Ireland Lighthaum Ireland
Head and Neck Cancer UK	Healthcare Improvement Scotland
Independent Cancer Patients VoiceLet's Face it	 Medicines and Healthcare products Regulatory Agency
Macmillan Cancer Support	National Association of Primary Care
Maggie's Centres	National Pharmacy Association
Marie Curie	NHS Confederation
Mouth Cancer Foundation	NHS Wales Joint Commissioning
National Association of	Committee
Laryngectomee Clubs	Scottish Medicines Consortium
Oracle Head and Neck Cancer	Welsh Government
South Asian Health Foundation	
Specialised Healthcare Alliance	Possible comparator companies
Swallows Head & Neck Cancer	Amarox Ltd (cisplatin, capecitabine)
Support Group	Bristol Myers Squibb (paclitaxel)
Tenovus Cancer Care	Dr Reddys Laboratories (capecitabine)
Tellovus Galicel Gale	Genus (paclitaxel)
Healthcare professional groups	Glenmark Pharmaceuticals
Association of Cancer Physicians	(capecitabine)
British Association of Head and Neck	Hospira UK (cisplatin, gemcitabine,
Oncologists	carboplatin, fluorouracil, docetaxel,
British Association of Head and Neck	paclitaxel)
Oncology Nurses	Medac Pharma (fluorouracil)
British Association of Oral and	Ranbaxy Ltd (gemcitabine)
Maxillofacial Surgeons	Sandoz Ltd (cisplatin)
British Association of	Seacross Pharmaceuticals (docetaxel,
Otorhinolaryngologists	paclitaxel)
, 5 · · 9·- · ·	Synchrony Pharma (gemcitabine)



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Dietetic Association- Oncology Specialist Group British Geriatrics Society British Institute of Radiology British Oculoplastic Surgery Society British Oncology Pharmacy Association British Psychosocial Oncology Society British Skull Base Society Cancer Research UK Oral Health Foundation 	•
 Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society 	 Associated Public Health groups Public Health Wales UK Health Security Agency
 Department of Health and Social Care NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.